CD147、PCNA、VEGF和MMPs在骨巨细胞瘤中的表达及临床意义

Expression of CD147,PCNA,VEGF and MMPs in giant cell tumor of bones and its clinical significance

背景:骨巨细胞瘤(giant cell tumor of bone,GCT)是一种具有低度恶性潜能的肿瘤,目前的主要治疗方法为临床手术治疗,局部侵袭性生长和术后复发率40%～50%,其病理学分级与影像学分型均不能对临床表现进行精确的预测,找到其他影响GCT生物学行为和预后的相关因素并寻找新的治疗途径尤为重要。目的:研究CD147、PCNA、VEGF、MMPs等分子在GCT组织中的表达,探讨其相互关系及与临床病理和预后的关系。方法:运用免疫组织化学S-P法,检测CD147、PCNA、VEGF、MMPs等分子在68例GCT患者中的表达,分析其相互关系以及与肿瘤临床病理资料、Jaffe分级及复发的关系。结果:CD147、MMP-2、MMP-9、VEGF阳性表达与患者年龄、性别等因素无关;CD147、MMP-2阳性表达在Jaffe各级之间有显著性差异(P<0.05),CD147、MMP-2、MMP-9在预后各分组间表达有显著性差异(P<0.05);CD147与MMP-9、VEGF、MVD、PCNA表达呈正相关(r=0.271,P=0.025;r=0.411,P=0.000;r=0.872,P=0.000;r=0.394,P=0.001)。结论:CD147与GCT的恶变、复发有关,并且和MMP-9、VEGF、MVD、PCNA的表达密切相关,可作为评价GCT恶性程度和判断预后的重要指标,并可作为化学治疗的新靶点。

Background： Giant cell tumor of bone （GCT） is a potential malignant tumor, and the main treatment is clinical surgery. Local aggressive growth and postoperative recurrence scale to all as high as 40% - 50%. The pathology classification andimage of GCT cannot precisely predict its clinical behavior, so it＇s very important to find a new way of treatment and other factors which relate to GCT＇s biological behavior and prognosis. Objective： To study the expression of CD147, PCNA, VEGF and MMPs in GCT and its relationship to clinical pathology and prognosis.Methods： The expression level of CD147, PCNA, VEGF and MMPs in 68 patients with GCT was detected by S-P immunohiso- chemistry. The relationship between each other, the clinical pathological data, Jaffe classification and recurrence was analyzed. Results ： The significant difference of expression level of CD147 and MMPs was found in the cases of GCT with Jaffe grad- ing, prognosis （P 〈 0. 05）, but not with the age and gender of the patients. The expression of CD147 was positively corre- lated to MMP-9, VEGF, MVD and PCNA （r =0. 271, P =0. 025; r =0. 411, P =0. 000; r =0. 872, P =0. 000; r = 0.394, P =0. 001）.Conclusions： The expression level of CD147 in GCT is correlated with invasion and recurrence, and positively related to MMP-9, VEGF, MVD and PCNA. CD147 may be an important indicator in evaluating the malignant degree and prognosis of GCT, and can be a new target for chemotherapy.